Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An update from Mirum Pharmaceuticals ( (MIRM) ) is now available.
Mirum Pharmaceuticals reported preliminary net product sales of approximately $336 million for 2024, surpassing the guidance range. The company projects 2025 global net product sales between $420 million and $435 million, highlighting its growth and leadership in rare diseases with significant advancements in treatments such as volixibat and potential new therapies for conditions like Fragile X Syndrome.
More about Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for rare liver diseases such as cholestatic diseases and rare genetic neurology disorders. The company is known for its products like LIVMARLI, CHOLBAM, and CHENODAL, and is actively expanding its global footprint with commercial access in 30 countries.
YTD Price Performance: -1.71%
Average Trading Volume: 369,525
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.98B
For detailed information about MIRM stock, go to TipRanks’ Stock Analysis page.
